← Back to Screener
Royalty Pharma plc Class A Ordinary Shares (RPRX)
Price$49.30
Favorite Metrics
Price vs S&P 500 (26W)30.10%
Price vs S&P 500 (4W)0.74%
Market Capitalization$28.85B
P/E Ratio (Annual)37.42x
Indicated Dividend Yield (Annual)1.88%
All Metrics
P/CF (Annual)11.59x
Book Value / Share (Quarterly)$11.22
P/TBV (Annual)4.26x
Indicated Dividend (Annual)$0.88
Revenue Growth (3Y)2.06%
Cash Flow / Share (Quarterly)$1.37
Payout Ratio (TTM)49.06%
Price vs S&P 500 (YTD)25.26%
Net Profit Margin (TTM)32.42%
EPS (TTM)$1.37
10-Day Avg Trading Volume2.64M
EPS Excl Extra (TTM)$1.37
Revenue Growth (5Y)2.30%
EPS (Annual)$1.37
Dividend / Share (Annual)$0.65
ROI (Annual)5.00%
Net Profit Margin (5Y Avg)29.51%
Cash / Share (Quarterly)$2.59
P/E Basic Excl Extra (TTM)37.42x
Revenue Growth QoQ (YoY)4.78%
EPS Growth (5Y)-12.06%
P/E Normalized (Annual)37.42x
ROA (Last FY)3.93%
Revenue Growth TTM (YoY)5.06%
EBITD / Share (TTM)$2.74
ROE (5Y Avg)10.63%
Operating Margin (TTM)65.58%
Cash Flow / Share (Annual)$1.37
P/B Ratio4.45x
P/B Ratio (Quarterly)3.44x
Net Income / Employee (Annual)$8
EV / Revenue (TTM)15.63x
Net Interest Coverage (TTM)6.99x
ROA (TTM)4.12%
EPS Growth QoQ (YoY)8.75%
EV / EBITDA (TTM)24.06x
EPS Incl Extra (Annual)$1.37
Current Ratio (Annual)2.40x
Quick Ratio (Quarterly)2.40x
3-Month Avg Trading Volume3.59M
52-Week Price Return55.33%
EV / Free Cash Flow (Annual)46.94x
P/E Incl Extra (TTM)37.42x
Revenue / Employee (TTM)$24
Tangible BV / Share (Quarterly)$12.70
P/S Ratio (Annual)12.13x
Asset Turnover (Annual)0.12x
52-Week High$50.00
Operating Margin (5Y Avg)52.45%
EPS Excl Extra (Annual)$1.37
CapEx CAGR (5Y)-4.90%
26-Week Price Return38.85%
Quick Ratio (Annual)2.40x
13-Week Price Return24.35%
Total Debt / Equity (Annual)1.38x
Current Ratio (Quarterly)2.40x
Enterprise Value$37,177.553
Revenue / Share Growth (5Y)-5.71%
Asset Turnover (TTM)0.13x
Book Value / Share Growth (5Y)-2.00%
Revenue / Employee (Annual)$24
Pretax Margin (Annual)55.68%
Cash / Share (Annual)$2.59
3-Month Return Std Dev20.49%
Net Income / Employee (TTM)$8
EBITDA CAGR (5Y)-0.52%
EBITDA Interim CAGR (5Y)3.77%
ROE (Last FY)11.90%
Net Interest Coverage (Annual)4.67x
EPS Basic Excl Extra (Annual)$1.37
P/FCF (TTM)27.44x
Receivables Turnover (TTM)150.73x
EV / Free Cash Flow (TTM)46.94x
Total Debt / Equity (Quarterly)1.38x
EPS Incl Extra (TTM)$1.37
Receivables Turnover (Annual)150.73x
ROI (TTM)5.19%
P/S Ratio (TTM)12.13x
Pretax Margin (5Y Avg)50.23%
Revenue / Share (Annual)$4.21
Tangible BV / Share (Annual)$12.70
Forward P/E10.08x
Price vs S&P 500 (52W)20.23%
P/E Ratio (TTM)37.42x
EPS Growth TTM (YoY)-5.85%
Year-to-Date Return29.40%
5-Day Price Return3.24%
EPS Normalized (Annual)$1.37
ROA (5Y Avg)3.87%
Net Profit Margin (Annual)32.42%
Month-to-Date Return4.23%
Cash Flow / Share (TTM)$0.66
EBITD / Share (Annual)$2.74
EPS Growth (3Y)140.90%
Operating Margin (Annual)65.58%
LT Debt / Equity (Annual)1.32x
P/CF (TTM)11.59x
ROI (5Y Avg)5.00%
P/E Excl Extra (TTM)37.42x
LT Debt / Equity (Quarterly)1.32x
EPS Basic Excl Extra (TTM)$1.37
P/TBV (Quarterly)4.26x
Payout Ratio (Annual)49.06%
P/B Ratio (Annual)3.44x
Dividend / Share (TTM)$0.65
Pretax Margin (TTM)55.68%
Book Value / Share (Annual)$11.22
Price vs S&P 500 (13W)21.48%
Net Margin Growth (5Y)-6.73%
Dividend Yield (TTM)1.31%
Beta0.40x
P/FCF (Annual)36.42x
Revenue / Share (TTM)$4.27
ROE (TTM)11.89%
52-Week Low$31.58
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.21
4.29
4.19
4.19
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
RPRXRoyalty Pharma plc Class A Ordinary Shares | 12.13x | 5.06% | — | -12.06% | $49.30 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties, generating recurring revenue from fixed payments tied to the sales of commercial medications. The company receives royalties from a diversified portfolio of 35+ approved products across oncology, neurology, and rare genetic diseases, plus 10 development-stage candidates from major pharmaceutical companies including AbbVie, Johnson & Johnson, Biogen, and Vertex. This business model provides predictable cash flows from established market-leading drugs without the operational risks of drug development or commercialization.